B cells and their cellular neighborhoods, i.e., lymphoid aggregates (LAs) and tertiary lymphoid structures (TLS), have not been extensively studied in melanoma brain metastases (BM) or lung adenocarcinoma (LUAD) BM, despite their prognostic value and role in immunotherapeutic responses. In this study, we evaluated the...
Noor E. Nader, Alexandra Glathar, Elaine V. Byrnes et al.· Cancer Discovery· 0 citations
Purpose: SMARCB1-deficient renal medullary carcinoma (RMC) is an ultra-rare, lethal malignancy refractory to therapies approved for other renal cell carcinomas, and its rarity makes randomized trials logistically unfeasible. We investigated whether wild-type epidermal growth factor receptor (EGFR) is a therapeutically...
N. Zacharias, Eric S Rupe, Xinyue Chen et al.· Clinical Cancer Research· 0 citations
Background Lung cancer remains the leading cause of cancer-related deaths in the United States with over 124,000 estimated deaths for 2026. Previous studies have found that tumor-adjacent lung tissues may provide additional insight into the immune microenvironment of early-stage NSCLC. Methods Multiplex immunofluoresce...
Isabella Polic, Claudio J. Arrechedera, Jared K. Slone et al.· bioRxiv· 0 citations
This approach identified a unique peptide corresponding to FGFR2b, a splicing isoform of FGFR2, that demonstrated markedly higher tumor enrichment than the alternative FGFR2 isoform, FGFR2c.
N. Shah, Beatriz Alvarado-Hernandez, Xinyue Chen et al.· Clinical Cancer Research· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
